hs-10375

HS-10375 is an orally bioavailable, highly selective small molecule inhibitor targeting the epidermal growth factor receptor (EGFR) C797S mutation. It is being developed by Jiangsu Hansoh Pharmaceutical for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), particularly in patients who have developed resistance to earlier-generation EGFR tyrosine kinase inhibitors due to the C797S mutation. Preclinical studies demonstrated that HS-10375 potently inhibits EGFR phosphorylation and tumor growth in models harboring double or triple EGFR C797S mutations, with superior activity compared to third-generation EGFR TKIs. In early clinical trials, it has shown objective responses and an acceptable safety profile in heavily pretreated NSCLC patients[1][2][3][10].

Other names

HS-10375HS10375HS 10375